

5.90.14

Section:	Prescription Drugs	Effective Date:	April 1, 2021
Subsection:	Topical Products	Original Policy Date:	June 5, 2015
Subject:	Exelderm	Page:	1 of 4

Last Review Date: March 12, 2021

Exelderm

Description

Exelderm (sulconazole nitrate)

Background

Exelderm is used to treat skin infections such as jock itch (tinea cruris) and ringworm (tinea corporis). This medication is also used to treat a skin condition known as tinea (pityriasis versicolor), a fungal infection that causes a lightening or darkening of the skin of the neck, chest, arms, or legs. Sulconazole is an azole antifungal that works by preventing the growth of fungus (1).

Regulatory Status

FDA-approved indications: Exelderm is an azole antifungal indicated for the treatment of tinea cruris, and tinea corporis caused by *Trichophyton rubrum*, *Trichophyton mentagrophytes*, *Epidermophyton floccosum*, and *Microsporum canis*, and for the treatment of tinea versicolor. Effectiveness has not been proven in tinea pedis (athlete's foot) (1).

Safety and effectiveness of Exelderm in pediatric patients has not been established (1).

Related policies

Ecoza, Ertaczo, Jublia, Kerydin, Luzu, Oxistat

Policy

This policy statement applies to clinical review performed for pre-service (Prior Approval, Precertification, Advanced Benefit Determination, etc.) and/or post-service claims.

Section:	Prescription Drugs	Effective Date:	April 1, 2021
Subsection:	Topical Products	Original Policy Date:	June 5, 2015
Subject:	Exelderm	Page:	2 of 4

Exelderm may be considered **medically necessary** in patients 18 years of age or older with tinea cruris, tinea corporis and tinea versicolor and when the conditions indicated below are met.

Exelderm is considered **investigational** in patients less than 18 years of age and for all other indications.

Prior-Approval Requirements

Age 18 years of age or older

Diagnoses

Patient must have **ONE** of the following:

1. Tinea Cruris
2. Tinea Corporis

AND the following:

- a. Laboratory and clinical documentation of **ONE** of the following fungal species
 - i. *Trichophyton rubrum*
 - ii. *Trichophyton mentagrophytes*
 - iii. *Epidermophyton floccosum*
 - iv. *Microsporum canis*

OR

3. Tinea Versicolor

AND the following:

Inadequate treatment response, intolerance, or contraindication to a legend topical or oral antifungal medication

Prior – Approval *Renewal* Requirements

Age 18 years of age or older

Diagnoses

Patient must have **ONE** of the following:

Section:	Prescription Drugs	Effective Date:	April 1, 2021
Subsection:	Topical Products	Original Policy Date:	June 5, 2015
Subject:	Exelderm	Page:	3 of 4

1. Tinea Cruris
2. Tinea Corporis

AND the following:

- a. Laboratory and clinical documentation of **ONE** of the following fungal species
 - i. *Trichophyton rubrum*
 - ii. *Trichophyton mentagrophytes*
 - iii. *Epidermophyton floccosum*
 - iv. *Microsporum canis*

OR

3. Tinea Versicolor

AND the following:

NOT used in a previously treated location within last 12 months

Policy Guidelines

Pre - PA Allowance

None

Prior - Approval Limits

Duration 1 month

Prior – Approval *Renewal* Limits

Same as above

Rationale

Summary

Exelderm is an antifungal cream used topically to treat skin infections such as jock itch (tinea cruris) and ringworm (tinea corporis). This medication is also used to treat a skin condition known as pityriasis (tinea versicolor). Safety and effectiveness of Exelderm in pediatric patients has not been established (1).

Prior approval is required to ensure the safe, clinically appropriate and cost-effective use of Exelderm while maintaining optimal therapeutic outcomes.

Section:	Prescription Drugs	Effective Date:	April 1, 2021
Subsection:	Topical Products	Original Policy Date:	June 5, 2015
Subject:	Exelderm	Page:	4 of 4

References

1. Exelderm [package Insert]. San Antonio, TX; Sun Pharmaceutical Industries, Inc.; June 2018.

Policy History

Date	Action
June 2015	Addition to PA
December 2016	Annual editorial review and reference update Addition of age to renewal section Policy number change from 5.14.14 to 5.90.14
September 2017	Annual editorial review and reference update
September 2018	Annual editorial review and reference update Removal of the diagnosis of tinea pedis (athlete's foot) from initiation and renewal criteria per package insert.
September 2019	Annual review and reference update
September 2020	Annual review
March 2021	Annual review

Keywords

This policy was approved by the FEP® Pharmacy and Medical Policy Committee on March 12, 2021 and is effective on April 1, 2021.